Last Update 14:40
Thursday, 05 August 2021

New melanoma drugs improve chances of survival

Two new drugs using very different scientific approaches can extend survival among patients with the deadliest form of skin cancer

reuters, Monday 6 Jun 2011
Share/Bookmark
Share/Bookmark

Two new drugs are offering the first new hope for real progress in many years.

Advanced melanoma patients taking an experimental pill, vemurafenib, developed by Roche and Daiichi Sankyo were 63 percent less likely to die than patients given chemotherapy, according to a new trial presented on Sunday at a meeting of the American Society of Clinical Oncology in Chicago.

Dr. Paul Chapman of Memorial Sloan-Kettering Cancer Center in New York and the study's lead investigator called the results an "unprecedented level of difference" for patients with advanced melanoma, who typically survive just eight months on current treatments.

In a separate study presented at ASCO, previously untreated people with advanced melanoma treated with Bristol-Myers Squibb's Yervoy, or ipilimumab, plus chemotherapy lived an average of two months longer than people who got chemotherapy alone.Yervoy works by spurring the immune system to fight off the cancer. Vemurafenib is designed for use in patients with tumors that have a mutation in a gene known as BRAF that allows melanoma cells to grow. About half of all melanomas have the genetic aberration

 

 

Search Keywords:
Short link:

 

Latest

© 2010 Ahram Online.